NAFLD / MASLD Socioeconomic Impact: Costs, Productivity Losses, and the Global Burden

What Is the True Global Prevalence of MASLD, and Why Does It Drive Cost?

MASLD affects an estimated 1.5 billion adults worldwide, making it the most common chronic liver condition on earth. Prevalence has roughly doubled since 1990, tracking the parallel epidemics of obesity and type 2 diabetes. Because most patients are asymptomatic for years, diagnosis often occurs late, at a stage when management is far more expensive.

A 2022 systematic review and meta-analysis published in the Journal of Hepatology (N = 1,201,807 participants across 72 countries) estimated global NAFLD prevalence at 38.0% (95% CI: 33.9 to 42.3%), up from approximately 25% in earlier 2016 estimates. [1] This represents a staggering 67% increase in the estimated number of cases over six years.

Why Prevalence Translates Directly to Cost

Each stage of disease progression carries a discrete cost tier. Simple hepatic steatosis is relatively inexpensive to monitor. Once fibrosis advances to stage F3, F4, annual per-patient costs multiply four- to six-fold because of hospitalizations for decompensation, hepatic encephalopathy management, and surveillance imaging. A modeling study in Hepatology estimated that a U.S. MASLD patient who progresses to cirrhosis generates approximately $60,453 in annual direct medical costs, versus $2,646 at the steatosis-only stage. [2]

The Obesity and Diabetes Multiplier

Type 2 diabetes is present in roughly 22% of MASLD patients globally, and its co-occurrence accelerates fibrosis progression two- to threefold. [3] Because the U.S. Centers for Disease Control and Prevention (CDC) projects that 45% of American adults will have obesity by 2030, the MASLD cost trajectory will steepen considerably without effective population-level interventions. [4]

Direct Healthcare Costs of NAFLD / MASLD in the United States

The annual direct U.S. Healthcare expenditure attributable to NAFLD/MASLD has been modeled at approximately $103 billion. That figure, derived from a 2018 population-level cost-of-illness analysis, includes outpatient visits, diagnostic imaging, liver biopsies, pharmacotherapy for comorbidities, and inpatient admissions. [5]

Cost by Disease Stage

| Disease Stage | Mean Annual Direct Cost per Patient (USD) | |---|---| | Simple steatosis (F0, F1) | $2,600, $4,000 | | MASH without advanced fibrosis (F2) | $7,800, $11,000 | | Advanced fibrosis / pre-cirrhosis (F3) | $15,000, $24,000 | | Compensated cirrhosis (F4) | $30,000, $60,000 | | Decompensated cirrhosis / hepatocellular carcinoma | $70,000, $200,000+ |

Data are approximate, aggregated from published cost-of-illness models. [2, 5]

Outpatient and Diagnostic Expenditure

Liver biopsy, still considered the reference standard for fibrosis staging, costs $1,500, $3,000 per procedure and carries a 1-in-1,000 risk of serious complications. Transient elastography (FibroScan) costs $200, $600 but requires specialist equipment. The Endocrine Society's 2023 clinical practice guideline on metabolic syndrome recommends non-invasive fibrosis panels (FIB-4 index, NAFLD Fibrosis Score) as first-line triage tools to reduce unnecessary biopsy spending. [6]

Pharmaceutical Costs on the Horizon

The 2024 FDA approval of resmetirom (Rezdiffra) at 80 mg or 100 mg once daily for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2, F3) adds a new direct-cost line item. Rezdiffra carries a U.S. List price of approximately $47,400 per year. [7] The MAESTRO-NASH trial (N = 966) showed that resmetirom 100 mg achieved MASH resolution without fibrosis worsening in 29.9% of patients versus 9.7% placebo at 52 weeks (P<0.001). [8] At population scale, the cost-effectiveness of earlier treatment will depend on long-term reduction in cirrhosis-related hospitalizations.

Indirect Costs: Productivity Loss, Absenteeism, and Disability

Direct medical costs capture only part of the economic picture. Indirect costs, covering lost wages, reduced work capacity, and premature mortality, may equal or exceed direct costs in total economic burden analyses.

Absenteeism and Presenteeism

MASLD patients with symptomatic disease (fatigue, right-upper-quadrant discomfort, hepatic encephalopathy at advanced stages) show measurable reductions in work productivity. A 2020 analysis using the Work Productivity and Activity Impairment (WPAI) questionnaire found that NASH patients reported a mean overall work impairment of 29.4%, compared with 12.1% in age-matched non-liver-disease controls. [9] Presenteeism, working while ill at reduced capacity, accounted for the majority of that gap.

Short- and Long-Term Disability

As fibrosis advances, MASLD patients face increasing rates of short-term disability leave for hepatic decompensation events (variceal bleeding, ascites) and long-term disability for hepatic encephalopathy. A 2019 Swedish registry study found that NAFLD patients had a 1.9-fold higher rate of disability pension claims compared with matched population controls over a 15-year follow-up period. [10]

Premature Mortality and Lost Earnings

MASH-cirrhosis and hepatocellular carcinoma (HCC) cut working lives short. Five-year survival for HCC diagnosed at an advanced stage is below 5%. [11] The lost earnings and lost tax contributions of MASLD-related premature death represent a substantial but frequently uncounted societal cost.

The Global Economic Burden Outside the United States

The United States is not alone. Europe, Southeast Asia, and the Middle East each carry massive MASLD-related economic loads.

Europe

A 2018 analysis estimated the annual economic burden of NAFLD across eight European countries (Germany, France, Italy, United Kingdom, Spain, Romania, Russia, and Poland) at approximately €35 billion (~$38 billion USD at then-current exchange rates). [12] Germany alone accounted for roughly €7 billion of that total, driven by high hepatology specialist costs and advanced-stage hospitalizations.

Asia-Pacific

MASLD prevalence in East Asia ranges from 25% to 40%, and is rising fastest in South and Southeast Asia due to rapid dietary westernization. China is projected to carry the largest absolute MASLD-attributable cost burden by 2030, given a population base of 1.4 billion and an estimated NAFLD prevalence already exceeding 29% in urban adults. A 2021 modeling study projected that NAFLD-related costs in China could reach $3.7 billion annually by 2025 if progression rates remain unchanged. [13]

Middle East and North Africa

The MENA region has some of the highest NAFLD prevalence rates globally, with Saudi Arabia reporting population rates above 45% in some studies. [1] These figures carry enormous implications for health-system sustainability in countries that fund healthcare through sovereign wealth in the context of falling oil revenues.

Health Disparities: Who Bears the Greatest Burden?

MASLD does not distribute evenly across populations. Race, ethnicity, income level, and geography all shape who gets sick and who receives timely care.

Racial and Ethnic Disparities in Prevalence

Hispanic Americans carry the highest NAFLD/MASLD prevalence of any U.S. Ethnic group, at approximately 45 to 58%, compared with roughly 33% in non-Hispanic whites and 24% in non-Hispanic Black adults. [14] The excess risk in Hispanic individuals is partly explained by the PNPLA3 I148M variant (rs738409), which is present in approximately 49% of Hispanic adults versus 23% of European-ancestry adults. The variant roughly doubles the risk of fibrosis progression per allele. [15]

Income and Insurance Status

Lower-income patients with MASLD are less likely to receive FibroScan evaluation, specialist referral, or access to emerging therapies. A 2022 analysis in JAMA Network Open found that Medicaid-enrolled NAFLD patients had a 34% lower rate of hepatology referral than commercially insured patients with identical FIB-4 scores, after adjusting for geography. [16]

Geographic Disparities

Rural Americans with MASLD face particular access barriers. Hepatology practices are concentrated in urban academic centers, and the median distance to a hepatologist in rural counties exceeds 60 miles. Delayed specialist access correlates with later-stage diagnosis, higher inpatient costs, and worse mortality outcomes.

The NAFLD-to-MASLD Renaming: Economic and Public Health Implications

In November 2023, an international Delphi-consensus panel formally renamed nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD). The new nomenclature requires at least one of five cardiometabolic risk factors (overweight/obesity, impaired fasting glucose or type 2 diabetes, hypertension, hypertriglyceridemia, or low HDL-C) to be present for the MASLD label to apply. [17]

Why the Name Change Has Economic Consequences

The term "nonalcoholic" carried stigma that delayed patient self-disclosure and reduced care-seeking. A 2021 survey found that 48% of NAFLD patients attributed their diagnosis to personal behavioral failures, a perception that correlated with lower medication adherence and higher rates of loss to follow-up. Removing the alcohol-reference framing may improve engagement.

The MASLD criteria also formally align fatty liver disease with the broader metabolic syndrome classification system used by cardiology and endocrinology guidelines. That alignment opens pathways for bundled metabolic risk management reimbursement codes, potentially changing how insurers pay for multidisciplinary care.

Reimbursement and Coding Changes

The ICD-10 transition from K76.0 (fatty [change of] liver, not elsewhere classified) to the emerging MASLD-specific codes is still in progress as of 2025. Accurate coding is essential for population surveillance, health technology assessment, and drug approval cost-effectiveness modeling. Miscoding currently leads to undercount of MASLD cases in claims databases, which in turn underestimates the true economic burden.

MASH-Cirrhosis as the Leading Indication for Liver Transplant: A Cost Crisis

MASH-cirrhosis surpassed hepatitis C as the leading indication for liver waitlisting in the United States in 2017 and continues to grow. [18] A single liver transplant carries direct costs exceeding $300,000 for the procedure itself, plus roughly $30,000, $50,000 annually in immunosuppression and post-transplant monitoring for the remainder of the patient's life.

Organ Scarcity and Cost-Per-QALY Implications

The United States performs approximately 9,500 liver transplants per year against a waitlist that consistently exceeds 10,000 patients. Each MASH patient who receives a transplant displaces another candidate. The incremental cost-effectiveness ratio (ICER) of a liver transplant for MASH-cirrhosis, compared with palliative management, is estimated at $50,000, $80,000 per quality-adjusted life year (QALY). [19] That sits within the standard U.S. Willingness-to-pay threshold of $100,000, $150,000 per QALY, but only when five-year graft survival exceeds 70%, which it does for carefully selected MASH recipients.

Recurrence After Transplant

MASLD can recur in the transplanted liver if underlying metabolic risk factors are not controlled. Recurrence rates of histologic MASLD exceed 70% at five years post-transplant in patients with persistent obesity. [20] Recurrence adds to long-term monitoring costs and creates a secondary burden on the transplant system.

Workplace and Employer Costs

Employers bear a measurable share of the MASLD burden through higher insurance premiums, disability payouts, and lost productivity.

Employer Health Insurance Premium Impact

A 2021 actuarial analysis estimated that an employee with NASH at the fibrosis stage costs an employer-sponsored health plan approximately $8,300 more per year than an age- and sex-matched employee without liver disease. [21] For a company with 10,000 employees and a 5% MASLD-with-fibrosis prevalence (conservative estimate), that translates to a $4.15 million annual excess cost.

Occupational Groups at Higher Risk

Shift workers face elevated MASLD risk due to circadian disruption and associated metabolic derangements. A 2020 meta-analysis found that rotating shift workers had a 1.29-fold higher odds of NAFLD compared with day-shift workers (OR 1.29, 95% CI 1.13 to 1.47). [22] Industries with high shift-work exposure, including healthcare, manufacturing, and transportation, carry a disproportionate workforce burden.

Prevention Economics: Why Investing Upstream Saves More

Prevention and early-stage intervention are substantially cheaper than managing advanced disease. The American Association for the Study of Liver Diseases (AASLD) 2023 guidance on MASLD management states: "Weight loss of 10% or more is associated with histological improvement in steatohepatitis and fibrosis in the majority of patients who achieve it, representing the most cost-effective intervention available for non-cirrhotic MASLD." [23]

GLP-1 Receptor Agonists as a Cost-Offset Intervention

Semaglutide 2.4 mg (Wegovy) is not currently FDA-approved specifically for MASH, but the ESSENCE trial (NCT04822181) is evaluating it in biopsy-confirmed MASH with fibrosis stage F2, F3. Interim data presented at EASL 2024 showed that semaglutide 2.4 mg achieved MASH resolution without worsening fibrosis in 62.9% of participants versus 34.3% placebo. [24] If approved, the cost-effectiveness calculus will depend on whether GLP-1-mediated weight loss and MASH resolution durably reduce downstream cirrhosis rates. At a list price of approximately $16,000, $17,000 per year, semaglutide's cost-per-QALY in MASH could be favorable if it prevents even a fraction of projected cirrhosis transitions.

Lifestyle Intervention Cost-Effectiveness

Structured lifestyle programs delivering 7 to 10% weight loss cost approximately $1,200, $2,400 per participant in U.S. Commercial programs. A 2019 Markov modeling study found that lifestyle intervention in NAFLD patients with F2, F3 fibrosis produced a cost savings of $5,100 per patient over a 10-year horizon compared with usual care, driven by reduced cirrhosis transitions. [25]

What Clinicians and Policymakers Should Prioritize

The economic data point toward three areas where targeted action could reduce MASLD's socioeconomic burden.

Universal Metabolic Screening With FIB-4

The FIB-4 index (age × AST / [platelet count × ALT^0.5]) costs nothing beyond a standard metabolic panel. FIB-4 <1.30 reliably rules out advanced fibrosis (negative predictive value above 90%), and FIB-4 >2.67 warrants specialist referral. The American Diabetes Association (ADA) 2024 Standards of Care recommend FIB-4 calculation for all type 2 diabetes patients at their annual visit, acknowledging the high MASLD-to-MASH prevalence in this group. [26]

Addressing Disparities Through Policy

Medicaid reimbursement parity for hepatology services, expanded telemedicine coverage for rural patients, and community-based metabolic health programs targeting Hispanic and lower-income populations could meaningfully reduce the disparity gap. Federal 1115 waiver programs that bundle obesity management with MASLD monitoring represent one structural mechanism already being piloted in three states.

Early Pharmacological Intervention to Reduce Downstream Costs

The FDA approval of resmetirom creates a defined treatment window at F2, F3 that may prevent progression to the far more expensive F4-cirrhosis stage. Cost-effectiveness analyses submitted to FDA during resmetirom's review estimated an ICER of approximately $48,000, $72,000 per QALY gained in the non-cirrhotic MASH population, within standard thresholds. Payers that restrict coverage to late-stage MASH may actually increase total expenditure by allowing cheaper-to-treat patients to progress to the costliest disease stages.

Clinicians should calculate FIB-4 at every annual metabolic visit for patients with obesity, type 2 diabetes, or two or more components of metabolic syndrome, referring those with FIB-4 >1.30 for vibration-controlled transient elastography or specialist evaluation rather than waiting for overt hepatic symptoms.